Quarterly report pursuant to Section 13 or 15(d)

Condensed Combined and Consolidated Statements of Operations (Parenthetical)

v3.19.3.a.u2
Condensed Combined and Consolidated Statements of Operations (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Research and Development Expense [Member]        
Share-based compensation expense $ 311 $ 198 $ 2,683 $ 997
Research and Development Expense [Member] | Roivant Sciences Ltd. (RSL) [Member]        
Costs allocated from related party 0 475 152 3,209
General and Administrative Expense [Member]        
Share-based compensation expense 1,103 39 2,440 78
General and Administrative Expense [Member] | Roivant Sciences Ltd. (RSL) [Member]        
Costs allocated from related party $ 487 $ 637 $ 1,001 $ 930